Business Wire

OUTSYSTEMS

28.10.2019 13:06:06 CET | Business Wire | Press release

Share
3,000 Attendees Will Pack RAI Amsterdam Center for World’s Largest Low-Code Conference Series

OutSystems is bringing the world’s largest event series showcasing low-code development and digital transformation to RAI Amsterdam. More than 4,000 people will experience the sold-out conference series that was held in Denver on Oct 2-3 and now Amsterdam on Oct 29-30.

The conference series features world-class OutSystems customers showcasing their low-code success stories and sharing best practices in redefining their digital futures. Customers speaking in Amsterdam include ISB Global, Prosegur, Heijmans, GEMS Education, Spotcheck, Yonder, Medtronic, De Efteling, PLUS Retail, Abu Dhabi Social Support Authority, Rainforest Alliance, CoolProfs, Valuga, Midland Heart Housing Association, Banco Santander, Total Produce plc, Randstad, and COOP Supermarkets.

Deloitte, one of the diamond sponsors for the conference, will demonstrate a number of low-code solutions they have developed with OutSystems including a call center application that uses artificial intelligence and speech recognition to detect the emotions of inbound callers.

John Rymer, Forrester vice president and principal analyst serving application development & delivery professionals, will co-headline the Amsterdam event and discuss how low-code is spreading throughout the enterprise. A true technology visionary, Rymer, coined “low-code” in 2015 after witnessing its massive potential for new, agile development technologies. Rymer will reveal his predictions on the future of app dev and his perspectives on the impact on business everywhere.

Diamond sponsor, Persistent, will showcase innovative stories from customers transforming their core business using digital software and services to improve the customer experience and automate business processes.

Attendees will get an up-close look at how low-code is enabling enterprises of all sizes to reinvent their businesses and achieve unprecedented levels of ROI. Hearing from OutSystems executives, customers and partners, along with industry thought leaders, attendees will walk away inspired by the many ways they can solve business problems using OutSystems technology.

“NextStep has established itself as the preeminent event for the low-code world to come together to learn, connect, and get motivated,” said OutSystems CEO and co-founder Paulo Rosado. “We’re thrilled to attract such a distinguished group of customers, partners, and industry thought leaders to Amsterdam. Attendees will come away with valuable insights that they can use to develop their careers, transform their business, and innovate.”

NextStep 2019 is sponsored by OutSystems partners and customers. Diamond Sponsors include Deloitte, Persistent Systems and everis. Platinum Sponsors include Valuga, Product League, Noesis, CoolProfs, Enterprise Touch, IG&H, ADA with partner Askblue, and Motion10. There are six Gold Sponsors: Outfit, ROFF, Truewind, NovioQ, KPMG, and Workato. Silver Sponsors include Incentro, StormyB, Transfer Solutions, myBrand, Nuveon Group, agentbase, and Capgemini. Networking Sponsors include Hi Interactive, Do iT Lean, Glintt, Headfitted Solutions, Keep it Simple, and Green Lemon Company.

To join the NextStep conversation on Twitter, use the #nxStep tag. For more information about OutSystems, visit www.outsystems.com .

About OutSystems - Thousands of customers worldwide trust OutSystems, the number one low-code platform for rapid application development . Engineers with an obsessive attention to detail crafted every aspect of the OutSystems platform to help organizations build enterprise-grade apps and transform their business faster. OutSystems is the only solution that combines the power of low-code development with advanced mobile capabilities, enabling visual development of entire applications that easily integrate with existing systems. Visit us at www.outsystems.com or follow us on Twitter @OutSystems or LinkedIn at https://www.linkedin.com/company/outsystems .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye